HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McDevitt, L. M. Search for Related Content PubMed PubMed Citation Articles by McDevitt, L. M.

LISA M. MCDEVITT, PHARM.D., BCPS, is Assistant Professor of Pharmacy Practice at the Massachusetts College of Pharmacy and Health Sciences and Clinical Specialist in Organ Transplantation at Tufts-New England Medical Center, 179 Longwood Avenue, Boston, MA 21150 (lisa.mcdevitt{at}bos.mcphs.edu).

Purpose. The characteristics, etiology, natural history, and direct and indirect effects of CMV disease in solid organ transplant recipients are described. Summary. CMV is a common herpesvirus that may be present in the donor or recipient of a solid organ transplant. Even though it is rarely pathogenic in healthy patients, transplant recipients are at risk for CMV viremia and symptomatic disease due to their immune-suppressed status. In addition to symptoms directly attributed to active disease, CMV can have a variety of indirect effects. Indirect effects may include additional infectious complications, posttransplant lymphoproliferative disease, allograft rejection, allograft loss, or death. The three most prevalent risk factors for CMV infection are CMV seronegativity in a recipient of an organ from a CMV-seropositive donor, the type of organ transplanted, and the degree of immune suppression. CMV prophylaxis is effective at preventing disease, but may result in a delayed onset where CMV disease occurs once the prophylaxis is stopped. Conclusion. Knowledge of risk factors for CMV infection and disease, the natural history in transplant recipients, and its direct and indirect effects will help clinicians make appropriate decisions regarding the use of preventive strategies. Index terms: Antivirals; Cytomegalovirus infections; Immunosuppressive agents; Transplantation

 

This article has been cited by other articles:

				M. Michaelis, T. A. T. Ha, H. W. Doerr, and J. Cinatl Jr Valproic acid interferes with antiviral treatment in human cytomegalovirus-infected endothelial cells Cardiovasc Res, February 1, 2008; 77(3): 544 - 550. [Abstract] [Full Text] [PDF]